Message Font: Serif | Sans-Serif
No. of Recommendations: 1

Gilead's Smart Risk
By Brian Gorman
October 2, 2006

Gilead Sciences' (Nasdaq: GILD) acquisition party rolls on. In its biggest deal yet, the company announced today that it will purchase fellow drug developer Myogen (Nasdaq: MYOG) for $2.5 billion in cash. Gilead's stock is taking a hit at the moment, perhaps because of worry about the acquisition's price tag. However, investors can rest assured that this deal rests on sound thinking......
Print the post  


When Life Gives You Lemons
We all have had hardships and made poor decisions. The important thing is how we respond and grow. Read the story of a Fool who started from nothing, and looks to gain everything.
Contact Us
Contact Customer Service and other Fool departments here.
Work for Fools?
Winner of the Washingtonian great places to work, and Glassdoor #1 Company to Work For 2015! Have access to all of TMF's online and email products for FREE, and be paid for your contributions to TMF! Click the link and start your Fool career.